Evaluating Dupilumab for Placement in a Value-Based Health PlanByLarry HanoverMay 10th 2021Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.